United Kingdom-based GSK has commenced a phase III clinical development programme with otilimab, an investigational anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, it was reported yesterday.
The product is intended for patients with moderate to severe rheumatoid arthritis who have had an inadequate response to disease modifying anti-rheumatic drugs or targeted therapies.
The product's progression into phase III follows the results of the phase II BAROQUE study, which were announced in October 2018. The phase III clinical programme (named 'ContRAst') is the first in RA to include head-to-head comparisons of otilimab with current treatments across all pivotal studies. It compares otilimab against two treatments with different modes of actions: tofacitinib (a Janus Kinase (JAK) inhibitor) and sarilumab (an anti-IL6). The programme also enrols a broad range of difficult-to-treat patients who have had an inadequate response to or have been unable to tolerate currently available treatments. It includes three pivotal studies and a long-term extension study. The primary endpoint for the pivotal studies is the proportion of patients achieving the American College of Rheumatology criteria (ACR20) at week 12 (against placebo).
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer